Life changing fever, headache and painkilling drug for children on the NHS
NHS England is to fund a life-changing treatment for people with rare conditions causing repeated bouts of fever, joint pains and swelling, in an effort to help a small group of people who ‘suffer in silence’.
Periodic fever syndromes (PFS) are a group of rare genetic conditions where the person’s immune system overreacts, resulting in frequent inflammation ‘flares’, involving chest or joint pains, headaches, mouth ulcers and skin rash.
On World Rare Diseases Day (Saturday 29 February) the NHS confirmed a deal has been struck for the drug – canakinumab – which modifies the immune system, turning off the inflammation process, significantly reducing the number of ‘flares’ children and adults experience.
The deal with a global pharmaceutical firm has been agreed after negotiations led by the NHS, as part of a major programme to ramp up access to innovative treatments, while freeing up funding for frontline patient care through smarter procurement.
The agreement brings into the NHS a more effective, convenient drug with fewer side effects than existing treatments, and follows contracts agreed in recent months which introduced new drugs for restoring sight and cystic fibrosis.
Sir Simon Stevens, chief executive of NHS England, recently said:
“Some illnesses affect a small number in a big way, which is why the NHS is increasingly bringing innovative, specialised and targeted treatments to people who need them.
“This latest new treatment has the potential to significantly improve the lives of children who bear the burden of bouts of crippling pain which blights lives and puts strain on families. It’s the latest in a line of major deals NHS England has successfully negotiated, which show that when drug companies play ball with the NHS, taxpayers get a fair deal and patients get cutting-edge treatments.”
There are around 168 patients in England with these diseases, both children and adults, and around 80% of these would be prescribed canakinumab.
The discounted price of canakinumab, developed by Novartis, is commercial in confidence.
Patients with three different types of periodic fever conditions will be eligible for treatment: familial Mediterranean fever, mevalonate kinase deficiency (also known as the hyperimmunoglobulinemia D syndrome), and tumour necrosis factor receptor–associated periodic syndrome (TRAPS).
Symptoms include high temperature, severe fatigue, severe abdominal, chest or joint pains, headaches, rashes and mouth ulcers, and flares can last several days or even weeks, with long term risk of organ failure or even death if not treated.
Current treatments which include anti-inflammatory and immune-suppressing drugs such as high dose steroids and ibuprofen are not always effective, and some may cause side effects including weight gain, skin and bone thinning and susceptibility to diabetes and infections.
Another treatment option is Anakinra which does not work for everyone and is taken daily via an injection which can be unpleasant for patients. Canakinumab is only injected every 8-12 weeks and is transformative – allowing patients to live more normal lives.
The NHS has struck a string of ‘smart deals’ struck to drive value for the taxpayer and benefits for patients. These include:
- a deal to make ocrelizumab, an innovative multiple sclerosis drug available;
- a ground-breaking deal which could eliminate Hepatitis C;
- a £300 million saving after negotiating deals with five manufacturers on low cost versions of the health service’s most costly drug, adalimumab, for arthritis;
- striking the first full access deal in Europe for CAR-T therapy via the Cancer Drugs Fund, which can potentially cure some children and adults with blood cancers where other treatments have failed;
- reaching a deal to make the life-extending lung cancer drug pembrolizumab available for routine use on the NHS;
- a deal to make nusinersen available – the first treatment that targets the underlying cause of spinal muscular atrophy.
Latest News from
NHS to launch ground breaking online COVID-19 rehab service06/07/2020 16:15:00
Tens of thousands of people who are suffering long-term effects of coronavirus will benefit from a revolutionary on-demand recovery service, the head of the NHS yesterday announced.
NHS and St John Ambulance to recruit and train thousands of cadets06/07/2020 11:15:00
The NHS and St John Ambulance are joining forces for the NHS’ anniversary to recruit and train thousands of ‘NHS cadets’.
Around one million downloads of fitness app during lockdown as people stay fit02/07/2020 09:15:00
A fitness tool backed by the NHS has been adopted by hundreds of thousands of people seeking to get in shape during lockdown.
NHS patients among first in Europe to benefit from landmark deal for cystic fibrosis treatment01/07/2020 14:15:00
NHS patients in England will be some of the first people in Europe to benefit from a new “truly life-transforming” treatment for cystic fibrosis, health service chief executive Sir Simon Stevens yesterday announced.
Rankin unveils powerful portrait series dedicated to frontline staff to mark NHS birthday30/06/2020 09:15:00
Powerful and personal portraits of doctors, nurses and other NHS staff who responded to the COVID-19 pandemic, captured by acclaimed photographer Rankin, were yesterday unveiled to celebrate the NHS birthday.
NHS boosts support for pregnant black and ethnic minority women29/06/2020 14:15:00
The NHS is rolling out additional support for pregnant Black, Asian and Ethnic Minority (BAME) women, as new research shows heightened risks facing women from minority groups.
LGBT+ staff and allies launch first NHS virtual pride25/06/2020 14:15:00
NHS colleagues from across the country are being invited to enjoy an unprecedented online celebration of the LGBT+ community this Friday evening.
NHS Chief Executive pays tribute to “essential contribution” of Windrush generation23/06/2020 09:15:00
The head of the NHS in England Sir Simon Stevens yesterday marked Windrush Day 2020 by committing the NHS to drive further improvements in race equality across the health service.